Related Experiment Video
Updated: Mar 30, 2026
09:06
Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
Published on: December 12, 2025
876
MicroRNAs: An Apparent Switch for High-Altitude Pulmonary Edema
Perwez Alam, Neeru Saini, M A Qadar Pasha1
1CSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi-110 007, India. qpasha@igib.res.in.
Microrna (Shariqah, United Arab Emirates)
|November 4, 2015
Summary
MicroRNAs (miRNAs) play a crucial role in physiological adaptation to high altitude. This study explores their potential involvement in high-altitude pulmonary edema (HAPE) pathophysiology.
Area of Science:
- Physiology
- Genetics
- Molecular Biology
Background:
- High altitude (HA) environments present challenges to human physiology due to hypobaric hypoxia.
- While most individuals acclimatize, some develop HA-related disorders like high-altitude pulmonary edema (HAPE).
- Gene expression changes, including microRNAs (miRNAs), are critical for acclimatization and maintaining homeostasis under hypoxic conditions.
Purpose of the Study:
- To investigate the potential role of microRNAs (miRNAs) in the pathophysiology of high-altitude pulmonary edema (HAPE).
- To explore the in-silico interactions and functions of miRNAs relevant to HAPE.
Main Methods:
- An in-silico study was conducted using existing literature.
- Analysis focused on target-based networking of miRNAs implicated in hypoxic responses.
Main Results:
- Several miRNAs (e.g., miR-16, miR-20b, miR-22, miR-206, miR-17/92) showed decreased expression under hypoxia, potentially affecting ion channels and pulmonary arterial pressure.
- Other miRNAs (miR-23b, miR-26a, miR-155) were found to inhibit TGF signaling, and miR-210 was noted to inhibit mitochondrial function.
- Observed miRNA functions align with physiological changes associated with HAPE.
Conclusions:
- Differential expression of miRNAs under hypobaric hypoxia may modulate human physiology.
- Further validation is required to confirm the specific role of these miRNAs in HAPE pathophysiology.
More Related Videos
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
559
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
559
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:25Mitral Regurgitation III: Medical Management
575
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
575
01:28Mitral Regurgitation IV: Nursing Management
522
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
522
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
643
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
643
01:30Pulmonary Hypertension: Classification and Pathogenesis
847
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
847